Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2009

View Archived Issues

Novel antibiotics synthesized at Cubist Pharmaceuticals

Phase II data support further development of EndoTAG/gemcitabine in pancreatic cancer

Vandetanib fails to meet primary endpoint in phase II trial in HCC patients

PK/PD data on the GLP-1 receptor agonist AVE-0010 presented at recent EASD meeting

INCB-13739 added to metformin improves HbA1c and LDL-C in type 2 diabetes patients

BI-10773 exhibits promising preclinical antidiabetic activity in rodent models

Novel 5-HT2C receptor agonist PF-3246799 shows favorable activity in animal models

Helix BioPharma presents update on development of topical interferon alpha-2b and L-DOS-47

Merz reports results from phase III study of NT-201 in post-stroke upper limb spasticity

Quest Diagnostics initiates DNA testing for Plavix response in coronary heart patients

Epigenomics launches Epi proColon blood test for early detection of colorectal cancer

Keryx initiates phase II perifosine study in CLL and SLL

Cipher begins enrollment in phase III CIP-Isotretinoin trial in severe nodular acne

Promising preclinical data support TRK-380 as a novel candidate for OAB treatment

Antisoma to amend primary endpoint of phase III trial of AS-1413 in AML

Relypsa initiates enrollment in phase IIb trial of RLY-5016 for hyperkalemia

Sanofi pasteur reports results from studies of Panenza and Humenza vaccines

IDEA reports results from two phase III studies of Diractin for osteoarthritis of the knee

Novartis gains exclusive worldwide rights to broad-spectrum PTK-0796 antibiotic from Paratek

European Commission approves Baxter's Celvapan H1N1 pandemic influenza vaccine

Cellceutix reports results of KM-133 study in human xenograft mouse model of psoriasis

Nymox reports results from phase II clinical trial of NX-1207 for BPH

FDA approves Daiichi Sankyo's sNDA for Welchol in pediatric patients with heFH

Novel antibacterial agents described by LEAD Therapeutics

Novel Jak2 inhibitors disclosed by Rigel for the treatment of cancer

Muscarinic M3 receptor antagonists claimed by AstraZeneca and Argenta Discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...